News
A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results